Evoke Pharma (NASDAQ:EVOK) Stock Price Passes Below 200 Day Moving Average – Here’s Why

Evoke Pharma, Inc. (NASDAQ:EVOK) shares passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $5.49 and traded as low as $4.28. Evoke Pharma shares last traded at $4.70, with a volume of 153,973 shares trading hands.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on Evoke Pharma in a research note on Wednesday. They set a “sell” rating on the stock.

Evoke Pharma Trading Up 7.6 %

The firm has a market capitalization of $7.00 million, a PE ratio of -0.43 and a beta of 0.36. The firm has a 50 day simple moving average of $5.12 and a 200 day simple moving average of $5.49.

Hedge Funds Weigh In On Evoke Pharma

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new position in Evoke Pharma, Inc. (NASDAQ:EVOK) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned about 1.42% of Evoke Pharma at the end of the most recent reporting period.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.